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AbstrACt
Introduction Foot ulceration is a multifactorial 
complication of diabetes. Therapeutic insoles and footwear 
are frequently used to reduce elevated tissue pressures 
associated with risk of foot ulceration. A novel protocol 
using in-shoe pressure measurement technology to 
provide an instant optimised insole and house shoe 
solution has been developed, with the aim of reducing foot 
ulceration.
Aim This study aims to assess the feasibility of 
conducting a multicentre randomised controlled trial to 
compare the effectiveness of a novel instant optimised 
insole with a standard insole for people with diabetic 
neuropathy.
Methods and analysis This study is a participant and 
assessor blinded, randomised, multicentre parallel group 
feasibility trial with embedded qualitative study. Seventy-
six participants will be recruited from three podiatry clinics 
and randomised to an optimised insole plus usual care 
(intervention group) or standard insole plus usual care 
(control group) using a minimisation by randomisation 
procedure by study centre and previous ulcer status. 
Assessment visits and data collection will be at baseline, 
3 months, 6 months and 12 months. Feasibility and 
acceptability of the trial procedures will be determined in 
terms of recruitment and retention rates, data completion 
rates, intervention adherence and effectiveness of 
the blinding. Assessment of the appropriateness and 
performance of outcome measures will inform selection 
of the primary and secondary outcomes and sample 
size estimate for the anticipated definitive randomised 
controlled trial. Clinical outcomes include incidence 
of plantar foot ulceration and change in peak plantar 
pressure. Twelve participants (four from each centre) and 
three treating podiatrists (one from each centre) will be 
interviewed to explore their experiences of receiving and 
delivering the intervention.
Ethics and dissemination The study was approved 
by the South-West Exeter Research Ethics Committee. 
Findings will be disseminated through conference 
presentations, public platforms and academic publications.
trials registration number ISRCTN16011830; Pre-
results.
IntroduCtIon   
Foot ulceration is a devastating multifactorial 
complication of diabetes. It is expected that 
25% of people with diabetes will develop a 
foot ulcer at some point.1 Foot ulceration is 
a limb and life-threatening condition known 
to precede 80% of all diabetic lower limb 
amputations.2 
It is estimated that 30% of people with 
diabetes have diabetic peripheral neuropathy, 
a primary risk factor for the development of 
foot ulceration.3 The forefoot region is most 
susceptible to foot ulceration, particularly in 
neuropathic feet absent of protective sensa-
tion, where plantar loads and tissue stress 
strengths and limitations of this study
 ► This study assesses the feasibility of undertaking a 
definitive robustly designed large-scale randomised 
controlled study.
 ► This study contributes to the limited literature on 
feasibility of reducing foot ulceration by insole and 
footwear provision for those at risk of diabetic foot 
ulceration.
 ► Qualitative aspects of this study will help inform 
future studies to optimise their acceptability to 
patients.
 ► The current study is not designed to find differences 
in outcomes.
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are increased.4–6 Therapeutic footwear and insoles are 
provided to offload and reduce harmful tissue stresses in 
people with diabetes.7 Guidelines for foot care for people 
with diabetes recommend the use of therapeutic footwear 
and insoles in the preventative management of those at 
risk of foot ulceration.8
The efficacy of offloading the diabetic, neuropathic 
foot through the use of therapeutic footwear and insoles 
varies considerably.7 9–12 This variability may be explained 
by different study designs, and a lack of consensus 
in prescriptions for therapeutic footwear and insoles 
between clinicians, clinics and services which are largely 
based on expert opinion and clinical experience.13 
There are no studies or protocols to indicate the optimal 
features or efficiency of the different devices designed to 
improve outcomes.
The use of an objective approach to guide footwear 
and insole design to improve clinical outcomes has 
been suggested. The use of pedobarography to identify 
vulnerable areas and influence the position and type of 
footwear and insole modifications may offer a more opti-
mised approach and improve offloading outcomes.14 Arts 
et al15 and Waaijman et al16 introduced modifications to 
therapeutic footwear and insoles guided by in-shoe pres-
sure technology, both noting reductions in peak pressure 
of 6.7%–24% and 15%–23%, respectively, compared with 
premodification. Lin et al17 used in-shoe technology to 
guide the defined removal of ‘plugs’ at sites of interest 
out of the insole and achieved 32% peak pressure reduc-
tion. However current protocols focus only on altering the 
distribution of pressure across the weight-bearing foot. 
As yet, no consideration has been given to the temporal 
aspect of gait. Specifically, that total contact area between 
foot to floor (and therefore insole function) is dependent 
on the phase of gait and gait style.
To our knowledge, this is the first protocol that uses 
pedobarography to categorise the temporal loading 
pattern of the foot according to gait style, combined 
with information from pressure patterns. This informa-
tion informs the design of insoles to optimally reduce 
in-shoe pressure through the implementation of a 
simple standardised algorithm. The insole is manufac-
tured and issued at the same appointment, avoiding 
detrimental delays. This protocol describes a feasibility 
study to assess the implementation of a novel insole 
design algorithm aimed at producing insoles which 
optimally reduce in-shoe peak pressure and subsequent 
ulceration risk in people with diabetes and neuropathy. 
Therefore, the purpose of this study is to assess if a defin-
itive randomised controlled trial (RCT) using a novel 
protocol is feasible.
Following recommendations from the Consolidated 
Standards of Reporting Trials (CONSORT) collabora-
tion18 19 this feasibility trial will allow operational expe-
rience to inform the conduct and final design of a 
definitive trial so that it can be successfully delivered with 
confidence.
objECtIvEs
The purpose of this feasibility study is to:
Assess the feasibility and acceptability of the trial pro-
cedures comparing the delivery of a novel instant op-
timised insole with a standard insole for people with 
diabetic neuropathy.
Select the most appropriate primary outcome measure 
and secondary outcome measures and inform the sam-
ple size calculation of the future RCT.
Explore the experiences of participants receiving opti-
mised instant insoles and Pulman house shoe, or flat-
bed cushioned inlay insole and Pulman house shoe, 
and podiatrists’ experiences of delivering the interven-
tion. This information will fine-tune the smooth de-
livery of the intervention protocol to optimise partic-
ipant engagement in terms of recruitment, insole and 
footwear adherence, and minimise loss to follow-up.
MEthods And AnAlysIs
trial design/setting
The Insoles to Ease Pressure (INSTEP) Study is a partic-
ipant and assessor blinded, randomised, multicentre 
parallel group feasibility trial with an embedded quali-
tative study. A CONSORT Study flow chart is presented 
(figure 1) which outlines the flow of participants through 
the trial. Seventy-six participants will be randomised (allo-
cation ratio 1:1) to receive an optimised insole plus usual 
care (intervention) or standard insole plus usual care 
(control). We will generate and implement the minimi-
sation by randomisation procedure through a web-based 
system. This will ensure equal numbers of participants in 
the two groups by location, study centres and by previous 
ulceration status. Intervention group allocation (in a 1:1 
ratio) will be revealed to the treatment podiatrist after the 
collection of baseline data. Insole and footwear will be 
issued by the same podiatrist immediately after randomi-
sation. The allocated insole will be worn for 12 months. 
After initial baseline assessment, outcome measures 
will be attained at 3 months, 6 months and 12 months 
postrandomisation.
A subsample of 12 trial participants (4 from each centre) 
and three treating podiatrists (one from each centre) 
will be purposely selected. Semistructured interviews 
will be used to qualitatively explore their experiences 
of receiving/delivering the intervention. In addition, 
a further six participants will complete a daily journal 
with a 1-week account of their experiences at 3 months, 
6 months and 12 months.
Trial centres are three community hospitals located 
in the south-west of England: Torbay (Torbay and South 
Devon NHS Foundation Trust), Exeter (Royal Devon and 
Exeter Foundation NHS Trust) and Solent (Solent NHS 
Trust).
Participants and recruitment
People with diabetes and neuropathy will be identified 
and initially screened for eligibility by the usual podi-
atry clinical team, while attending for a routine foot care 
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appointment located within the hospital-based multidis-
ciplinary diabetic team foot clinic or podiatry community 
clinic. The inclusion and exclusion criteria are presented 
in table 1. Potential participants will be given a brief verbal 
explanation of the trial by their treating podiatrist and 
provided with written information. They will have at least 
24 hours to review this information and ask any further 
questions before volunteering to participate. Potential 
participants will be telephoned to confirm their continued 
willingness to participate and offered an appointment for 
baseline measurement. Written informed consent will 
be obtained by a Good Clinical Practice trained nurse or 
podiatrist at the baseline visit.
Intervention
Two different insoles will be evaluated for feasibility and 
acceptability in this trial: instant optimised insole (inter-
vention) and cushioned inlay insole (control). Both 
insoles will be custom-made to foot size and constructed 
using materials commonly used in the manufacture of 
insoles for people with diabetes. Each insole will be fitted 
into a Pulman house shoe, which will be measured to fit 
the participants’ foot. In addition, both insoles will have 
an activated data logger (Orthotimer, Algeos, Liverpool, 
UK) embedded into the insole to measure adherence.
Optimised insole
The instant optimised insole will be designed and opti-
mised using the F-scan in-shoe pressure analysis system 
(Tekscan, Boston, Massachusetts, USA). A novel algorithm 
based on walking gait style (Mr Wobbly, Mr Stompee, Mr 
Propulsive) has been developed. The design and modi-
fication(s) will be informed by the treatment algorithm 
(online supplementary material 1). The optimised insole 
Figure 1 Trial flow chart. MDT, multidisciplinary diabetic 
team; NHS, National Health Service.
Table 1 Insoles to Ease Pressure (INSTEP) Study inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Confirmed diagnosis of type 1 or type 2 diabetes as confirmed 
by medical records
Any other significant disease or disorder*
Aged over 18 years Non-healing foot ulcer at another site that requires targeted 
offloading
Identified clinical need for offloading insoles by podiatrist Unable to walk 5 m with/without walking aid
Neuropathic (sensory peripheral diabetic neuropathy defined 
as insensitivity of a 5.07/10 g monofilament16)
Unable to stand on either leg independently for 10 s (±chair aid 
to assist in balance)
Palpable pedal foot pulses Lacking capacity or unwilling to give consent
Able and willing to comply with all trial requirements Already wearing existing insoles that are clinically appropriate
Peripheral vascular disease (non-reconstructible vascular 
disease as determined by arterial duplex)
Unwilling to wear therapeutic footwear
Gross foot deformity, for example, Charcot foot or fixed rear 
foot deformity
Unable to provide adequate consent to undertake the trial 
procedures
Major amputation of part of the foot
*Which, in the opinion of the principal investigator (PI), may put the participant at risk of health deterioration, such as falls.
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will consist of a preconstructed base (slim-flex, full-length, 
low-density, Shore A30, Algeos, UK). Regions of interest 
(ROIs) therein may be further formed to accommodate 
for prominent areas, with the addition of modifications 
that are designed to offload pressures from bony promi-
nences in specific regions. These will be used to reduce 
peak plantar pressure values in conjunction with real-time 
pressure data from the F-scan system in the specific ROIs.
Control insole
The control group will receive a flatbed cushioned inlay 
insole (3 mm Poron 4000) with 5 mm medium density 
EVA heel lift cut to shoe size.
study procedures
An overview of the study procedures are outlined in 
table 2. All participants will be invited to attend the 
baseline visit and three further study appointments at 
3 months, 6 months and 12 months postrandomisation. 
Data at all time points will be collected in case report 
forms (CRFs) by the trial team. All data will be entered 
into a secure database by the Peninsula Clinical Trials 
Unit.
Baseline visit (visit 1)
At visit 1, written informed consent will be obtained 
on arrival. In addition, clinical information will be 
obtained from the patient and their medical notes 
including demographics (gender, age, height, weight, 
smoker/non-smoker, ethnicity), medical history (type 1 
or type 2 diabetes, time since diabetes diagnosis, history 
of previous foot ulceration, current foot ulceration, other 
medical conditions), blood glycated haemoglobin levels 
and glomerular filtration rate. This information will be 
used to account for cofounding variables and analyses 
of differences and similarities between intervention arm 
groups.
data collection
Participants will perform in-shoe measurement tests 
with the treating podiatrist. The F-Scan in-shoe pres-
sure measurement system (Tekscan, Boston, Massachu-
setts, USA) is capable of reliable and repeatable data 
collection.20–22 The F-scan system sensors are connected 
to a computer via a cuff unit and a 9.14 m long cable. 
Data are collected at a sampling rate of 50 Hz for 4 s. The 
TekScan software identifies pressures from 960 sensing 
locations on the plantar foot. Plantar pressures can be 
identified from individual samples or peak pressures can 
be identified over a total stance phase.
To optimise the accuracy and repeatability of the data 
collected within this study the following precautions will 
be incorporated within the data collection protocol. New 
sensors will be provided for each participant for each 
individual foot, labelled and used to collect data from 
that foot throughout the duration of the study. Partic-
ipants will put on standard socks (20 denier stockings) 
and will be fitted with a standard house shoe (Markell 
Shoe Company, Yonkers, New York, USA). Any callus on 
the foot will be removed prior to fitting the socks and 
footwear, and prior to any recording.
Using a standardised protocol, participants will then 
be asked to undertake two test walks between chairs.23 24 
This will allow the determination of usual gait velocity 
and for acclimatisation of the sensors. Between the chairs 
a premarked 5 m walkway with a little extra at each end 
to allow for deceleration and acceleration of gait will be 
used to determine gait velocity (m/s). This will be calcu-
lated by stopwatch recording of the time taken to pass 
between the marks. The walks will allow for the sensors 
Table 2 Study procedures for the Insoles to Ease Pressure (INSTEP) Study
Procedure
Baseline 
clinic (visit 
1)
3 months* 
follow-up 
clinic (visit 2)
4 months 
qualitative
follow-up*
6 months* 
follow-up 
clinic (visit 3)
12 months* 
follow-up 
clinic (visit 
4)
Confirmation of eligibility X
Informed consent X
Demographics and history X
Plantar pressure in-shoe recording X X X X
Randomisation X
Intervention provision (including plantar pressure 
recording)
X
Outcome measures (ulcer incidence; photographs, 
activity and self-care questionnaires)
X X X X
Semistructured interviews (in participants’ homes) X
Journal entries X X X
Serious adverse event recording X X X X
*Postrandomisation.
5Collings R, et al. BMJ Open 2019;0:e029185. doi:10.1136/bmjopen-2019-029185
Open access
to bed in and the temperature to reach equilibrium. 
Before each data collection session each patient will 
be weighed and each pair of insoles calibrated against 
body weight. Following calibration, if sensor saturation 
pressure exceeds 2000 kPa the sensor will be discarded. 
Calibration will be checked for within-foot and between-
foot repeatability, and if excessive variation of ±10% is 
observed, the sensor will be recalibrated.
The test will consist of two runs initially. However, extra 
runs may be required if gait velocity is not consistent (a 
maximum of 5% deviation will be allowed). From each 
run, a minimum of three steps per foot is required to be 
analysed (excluding first and last steps of each run).
Using recorded F-Scan data, a maximum of three 
‘Regions of Interest’ can be identified for each partici-
pant, where ROI=mean peak pressure >350 kPa and/or is a 
recently healed ulcer site(s) or callus/corn formation. In addi-
tion, identification of type of gait style (Mr Wobbly, Mr 
Stompee, Mr Propulsive) by analysis of the recorded 
F-scan pressure time curve and force time curve will occur.
Follow-up visits
Postrandomisation at 3 months (visit 2), 6 months (visit 
3) and 12 months (visit 4) will occur. In-shoe pressure 
measurement testing, described in the baseline visit, will 
be repeated. Outcome measures will be collected at each 
visit. Participants who cease involvement in the study 
prior to the visits will be invited to report the reason. This 
will be optional.
outcome measures
Primary outcomes
The primary outcomes include feasibility and accept-
ability of the INSTEP Study. Quantitative and qualitative 
feedback will be obtained to identify the main deter-
minants of experience and acceptance of the INSTEP 
trial, in particular the following measures and opera-
tional criteria:
 ► Assessing numbers of eligible participants from the 
target population.
 ► Assessing recruitment and retention rates of eligible 
participants through the trial.
 ► Assessing the willingness of participants to be 
randomised.
 ► Assessing the pragmatism of delivering the insole 
intervention in the proposed settings.
 ► Measuring variation and fidelity in the delivery of the 
intervention in each group. A fidelity checklist will 
evaluate the adherence by the treating podiatrists to 
the standardised protocol of intervention delivery.
 ► Assessing the completeness of data sets/outcome 
measures.
 ► Assessing the success of the blinding.
Secondary outcomes
Anthropometric measurements of height and weight will 
be attained at baseline. In addition, sensory neuropathy,25 
visual acuity, clinician rated biomechanical foot and ankle 
status using validated clinical measures (foot posture 
index FP-6,26 ankle joint,27subtalar joint,28 first metatarsal 
phalangeal joint range of motion29) and clinician rated 
balance status (Romberg’s test)30 will be collected.
Clinical outcomes in the form of mean peak plantar 
pressure at ROI, in the standardised Pulman house 
shoe and measurements of plantar foot ulceration31 as 
measured by photograph following predefined assess-
ment criteria32 will be assessed at baseline, 3 months, 
6 months and 12 months. Adherence to wearing the 
insole and footwear (Pulman house shoe) as measured 
by a data logger (Orthotimer, Algeos, Liverpool, UK) will 
be recorded.
Patient self-reported outcomes will be assessed at base-
line, 3 months, 6 months and 12 months. The Nottingham 
Assessment of Functional Footcare Questionnaire33 is an 
instrument that is used in routine care to identify those 
whose usual foot care might put their feet at risk of future 
ulceration. The International Physical Activity Question-
naire34 is an instrument for monitoring of physical activity 
and inactivity.
Blinding
Every effort will be made to ensure the participants and 
the assessor (chief investigator) remains blinded to treat-
ment allocation until the end of the study. The chief 
investigator and the participants will complete a blinding 
assessment form after each measurement session to eval-
uate the effectiveness of the blinding. Successful blinding 
will be assessed using the Blinding Index.35
statistical analysis plan
A comprehensive statistical analysis plan (SAP) will be 
drafted prior to the final database lock; the SAP will be 
agreed with the trial steering committee (TSC) in the 
absence of a data monitoring committee. An extended 
CONSORT18 flow chart will be used to present descriptive 
data on screening, enrolment, intervention allocation, 
follow-up and assessment. It will also show any deviations 
from protocol, for example, participants receiving an 
‘incorrect’ treatment. Descriptive data will be presented 
by the intervention group on baseline characteristics, for 
example, age, sex, type of diabetes.
Proposed primary outcome analysis
Analyses will summarise the feasibility outcomes: data 
from screening, recruitment and follow-up logs will be 
used to generate realistic estimates of eligibility, recruit-
ment, consent and follow-up rates in the trial population. 
In addition, adherence data (eg, session attendance and 
insole/footwear adherence) will be used to contribute to 
the evaluation of the acceptability and concordance to the 
insole intervention. Completion rates will be estimated 
for each of the patient-reported and clinical outcome 
measures at each time point. All such estimates will be 
accompanied by appropriate CIs, to allow assumptions to 
be made in the planning of the definitive trial. The base-
line characteristics of individuals lost to follow-up will be 
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compared with those who complete the feasibility trial to 
identify any potential bias. Means and SDs arising from 
differences between the intervention and control arms to 
inform a power calculation for sample size estimate for 
the main RCT will be made.
Progression to a full trial will occur if the following 
minimum success criteria are achieved, or if there is 
reason to believe that suitable enhancements can be 
made to the full trial to ensure that any concerns are 
circumvented:
 ► 70% recruitment of the intended 76 participants 
within the 13-month recruitment window.
 ► 75% retention of participants within the 12-month 
trial period.
 ► 80% completion rate of primary and secondary 
outcome measures at baseline, 3 months, 6 months 
and 12 months.
Proposed secondary outcome analysis
Further analyses will summarise the proposed primary 
and secondary patient-reported and clinical outcomes 
at each time point. Descriptive statistics of the proposed 
primary and secondary outcomes will be produced, as 
appropriate for each measure for each trial arm. Interval 
estimates of the potential intervention effects, relative 
to control only, will be produced in the form of a 95% 
CIs, to ensure that the effect size subsequently chosen for 
powering the definitive trial is plausible, but no formal 
hypothesis testing will be undertaken of the feasibility 
data.
Qualitative analysis
Thematic analysis will be used for the analysis of the inter-
views and journals. This method includes a strategy for 
identifying themes and subthemes.36 The transcripts of 
the interviews and journal entries will be uploaded to the 
qualitative analysis program NVivo. To avoid individual 
bias, two researchers will independently read and code 
the transcripts. The codes will be formulated from the 
text fragments and will possibly be revised during the 
process of reading the transcripts. The two researchers 
will then discuss the results of the individual codes and try 
to reach consensus. After this, the codes will be reviewed 
and themes will be formulated.
Meaningful text fragments will be determined, as will 
codes (subthemes) and themes related to the trial objec-
tives. Data extracts will be accompanied by narrative to 
elaborate why the extract is analytically interesting.
All participants will be anonymised and pseudonyms 
used to demonstrate different participants’ experiences. 
If any information is disclosed during the trial that could 
pose a risk of harm to the participant or others, the 
chief investigator, where appropriate, will report and act 
accordingly.
Patient involvement
Patients were involved in the design and are currently 
involved in the conduct of this research. During the 
planning stage, priority of the research question, choice 
of outcome measures and methods of recruitment were 
informed by discussions with patients through a focus 
group session and two structured interviews. Patients 
form the membership of the independent TSC and of 
the trial management group. Once the trial has been 
published, participants will be informed of the results in 
a study newsletter suitable for a non-specialist audience.
data collection and management
Trial data collected at each centre by the research podi-
atrists and clinical research nurses will be recorded on 
trial-specific CRFs and will be considered the source 
data. The data manager will review the data being sent 
at regular intervals and report back to each centre if 
there is any discrepancy. The original completed CRF 
will be checked for completeness to ensure there are no 
missing items. Data will be entered into the database via 
a bespoke web-based data entry system encrypted using 
secure sockets layer (SSL).
sample size
As this is a feasibility trial the sample size is pragmatic and 
a power calculation is neither relevant nor possible. In 
this feasibility trial, while centres are likely to start recruit-
ment in a staggered fashion, our overall target recruit-
ment will be 2 per month per centre up to a total of 76 
participants (38 per group). A CI approach has been 
used to establish feasible adherence rates. Based on an 
estimated completion rate of 75%, at least 75 patients are 
required. This is based on obtaining a 95% CI for a single 
proportion with a specified lower bound of the CI of 0.70 
and a marginal error of 0.05. Data collected on proposed 
secondary outcomes will provide data on which sample 
size calculations can be performed in the future RCT.
Adverse events
Adverse events (AEs) are, according to the definitions, 
any unfavourable or unintended event affecting patients 
in the study. In cases of prolongation of hospitalisation, 
death or significant clinical sequelae, these events are 
defined as serious AEs (SAEs), the occurrence of which 
will be informed to the study sponsor and the TSC at short 
notice. During protocol treatment, all deaths, all SAEs 
that are life-threatening and any unexpected SAE must 
be reported to the chief investigator using the SAE form 
within 48 hours of the initial observation of the event. In 
this trial, only those non-serious AEs associated with the 
lower limb, foot and mobility need to be reported. Safety 
aspects of the study will be monitored by the TSC, which 
will receive unblinded data for its judgement.
To standardise and optimise implementation of the 
intervention, and to further ensure the safety and well-
being of research participants, all participants will be 
provided with standardised information on footwear and 
insole usage, how to increase wear time of the insoles, 
foot self-inspection and what to do in the event of a 
‘foot attack’. This information will be reiterated at each 
7Collings R, et al. BMJ Open 2019;0:e029185. doi:10.1136/bmjopen-2019-029185
Open access
appointment by the treating podiatrist. Participants will 
be advised to contact the treating podiatrist should any 
problems occur, in order that they can advise remanage-
ment of these issues.
Ethical issues
The protocol, V.1.0 (12/7/2017), was reviewed by the 
South-West Exeter Research Ethics Committee (REC) and 
was given a favourable opinion (REC ref 17/SW/0169) 
on 18 September 2017. Health Research Authority regu-
latory approval was given on 19 September 2017 and the 
study was adopted on the NIHR portfolio on 15 August 
2017. Plymouth University is the sponsor of the study. The 
study will comply with the International Conference for 
Harmonisation of Good Clinical Practice guidelines and 
the UK Framework for Health and Social Care Research
Amendments to the protocol or study documents will 
be submitted to the REC and can only be implemented 
once approval has been obtained. Amendments will be 
tracked in the protocol and the version of the protocol 
will be updated.
dissemination plan and impact
It is the intention that the results of this study will be 
published in peer-reviewed journals and presented at 
national and international conferences. Authorship 
will be determined per internationally agreed criteria 
for authorship. Participant-level data will be available 
following publication of results on request. Results will 
be disseminated to the patient and public community 
via social media, newsletter articles and presentations 
at patient conferences and forums, led by the patient 
partners.
dIsCussIon
The proposed study will allow for all information collected 
providing important parameters to consider running a 
large-scale RCT and to identify potential constraints and 
possible solutions.
Current trends in the provision of insoles and thera-
peutic footwear are diverse for people with diabetes 
and neuropathy at risk of foot ulceration.37 A scarcity of 
evidence base for the appropriate design, modification 
and manufacture results in a lack of clear guidance for 
clinicians. As healthcare systems are also moving towards 
personalised medicine, the use of an in-shoe pressure 
measurement system and insole paradigm that will guide 
and personalise insoles and therapeutic footwear with no 
manufacturing delays has been developed.
The main limitations of the study are those character-
istic of feasibility studies, the lack of power to present a 
statistically significant difference in outcomes. It may 
have a high dropout rate, so predictors of discontinu-
ation should be assessed comparing characteristics of 
compliant patients with those who were lost to follow-up.
However, and despite the aforementioned limitations, 
the findings and outputs from the proposed feasibility 
study will take us closer to designing a future cost-effec-
tive trial in people with diabetes and neuropathy at risk 
of foot ulceration.
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